Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
Glucotrack (Nasdaq: GCTK) has announced its participation in the FORGETDIABETES bionic pancreas initiative, funded by the EU's Horizon 2020 program with €75 Billion. The project aims to develop a long-term automated insulin delivery system for type 1 diabetes patients.
Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.
Led by Dr. Claudio Cobelli from the University of Padova, the project includes partners from Italy, Germany, and France. The initiative aims to transform diabetes management from a constant-attention disease to a manageable lifestyle condition, similar to wearing long-term contact lenses.
Glucotrack (Nasdaq: GCTK) ha annunciato la sua partecipazione all'iniziativa FORGETDIABETES per il pancreas bionico, finanziata dal programma Horizon 2020 dell'UE con 75 miliardi di euro. Il progetto mira a sviluppare un sistema automatizzato di somministrazione dell'insulina a lungo termine per i pazienti con diabete di tipo 1.
Il Monitor Continuo del Glucosio nel Sangue (CBGM) di Glucotrack sarà integrato nel sistema per fornire letture del glucosio in tempo reale. L'obiettivo dell'iniziativa è creare un pancreas bionico invisibile che elimini la necessità di interventi terapeutici e riduca il carico psicologico.
Guidato dal dott. Claudio Cobelli dell'Università di Padova, il progetto coinvolge partner da Italia, Germania e Francia. L'iniziativa punta a trasformare la gestione del diabete da una malattia che richiede attenzione costante a una condizione di vita gestibile, simile all'uso a lungo termine di lenti a contatto.
Glucotrack (Nasdaq: GCTK) ha anunciado su participación en la iniciativa FORGETDIABETES del páncreas biónico, financiada por el programa Horizonte 2020 de la UE con 75 mil millones de euros. El proyecto tiene como objetivo desarrollar un sistema automatizado de administración de insulina a largo plazo para pacientes con diabetes tipo 1.
El Monitor Continuo de Glucosa en Sangre (CBGM) de Glucotrack se integrará en el sistema para proporcionar lecturas de glucosa en tiempo real. La meta de la iniciativa es crear un páncreas biónico invisible que elimine la necesidad de acciones terapéuticas y reduzca la carga psicológica.
Liderado por el Dr. Claudio Cobelli de la Universidad de Padua, el proyecto incluye socios de Italia, Alemania y Francia. La iniciativa busca transformar el manejo de la diabetes de una enfermedad que requiere atención constante a una condición de vida manejable, similar al uso prolongado de lentes de contacto.
Glucotrack (나스닥: GCTK)는 EU의 Horizon 2020 프로그램에서 750억 유로의 자금을 지원받는 FORGETDIABETES 바이오닉 췌장 프로젝트에 참여한다고 발표했습니다. 이 프로젝트는 1형 당뇨병 환자를 위한 장기 자동 인슐린 전달 시스템 개발을 목표로 합니다.
Glucotrack의 연속 혈당 모니터(CBGM)가 시스템에 통합되어 실시간 혈당 수치를 제공합니다. 이 이니셔티브의 목표는 치료적 조치가 필요 없고 심리적 부담을 줄여주는 보이지 않는 바이오닉 췌장을 만드는 것입니다.
이 프로젝트는 파도바 대학의 클라우디오 코벨리 박사가 주도하며, 이탈리아, 독일, 프랑스의 파트너들이 참여합니다. 이 이니셔티브는 당뇨병 관리를 지속적인 주의가 필요한 질병에서 장기 콘택트렌즈 착용과 같은 관리 가능한 생활 조건으로 전환하는 것을 목표로 합니다.
Glucotrack (Nasdaq : GCTK) a annoncé sa participation à l'initiative du pancréas bionique FORGETDIABETES, financée par le programme Horizon 2020 de l'UE à hauteur de 75 milliards d'euros. Le projet vise à développer un système automatisé de délivrance d'insuline à long terme pour les patients atteints de diabète de type 1.
Le Moniteur Continu de Glucose Sanguin (CBGM) de Glucotrack sera intégré au système afin de fournir des mesures de glucose en temps réel. L'objectif de l'initiative est de créer un pancréas bionique invisible qui élimine le besoin d'actions thérapeutiques et réduit la charge psychologique.
Dirigé par le Dr Claudio Cobelli de l'Université de Padoue, le projet regroupe des partenaires d'Italie, d'Allemagne et de France. L'initiative ambitionne de transformer la gestion du diabète, d'une maladie nécessitant une attention constante, en une condition de vie maîtrisable, comparable au port prolongé de lentilles de contact.
Glucotrack (Nasdaq: GCTK) hat seine Teilnahme an der bionischen Bauchspeicheldrüsen-Initiative FORGETDIABETES bekanntgegeben, die vom EU-Programm Horizon 2020 mit 75 Milliarden Euro gefördert wird. Das Projekt zielt darauf ab, ein langfristig automatisiertes Insulinabgabesystem für Typ-1-Diabetes-Patienten zu entwickeln.
Der Kontinuierliche Blutzucker-Monitor (CBGM) von Glucotrack wird in das System integriert, um Echtzeit-Glukosewerte bereitzustellen. Ziel der Initiative ist es, eine unsichtbare bionische Bauchspeicheldrüse zu schaffen, die therapeutische Maßnahmen überflüssig macht und die psychische Belastung reduziert.
Leitung hat Dr. Claudio Cobelli von der Universität Padua, das Projekt umfasst Partner aus Italien, Deutschland und Frankreich. Die Initiative will das Diabetesmanagement von einer ständig überwachten Krankheit zu einem kontrollierbaren Lebensstil verwandeln, ähnlich wie das Tragen von Kontaktlinsen über einen langen Zeitraum.
- None.
- None.
Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
FORGETDIABETES is funded by the European Union's Horizon 2020 research and innovation program, a multi-year funding program with
“We are committed to the goal of revolutionizing treatment for people with type 1 diabetes, forever changing the medical approach towards this disease burden,” said Claudio Cobelli, PhD, Emeritus Professor of Bioengineering at the University of Padova in Padova, Italy, who serves as Coordinator for the initiative. “The longevity, accuracy and convenience of Glucotrack’s CBGM make it more automatic and less intrusive to daily living than other glucose monitoring methods and thus an ideal complement for our bionic pancreas technology.”
Despite significant advancements in diabetes technology, such as subcutaneous continuous glucose sensors and insulin pumps, daily management remains a substantial burden for many people living with diabetes. The FORGETDIABETES initiative aims to alleviate this burden by developing a groundbreaking bionic pancreas technology. This innovative solution seeks to transform diabetes from a disease that requires constant attention into a more manageable lifestyle condition, much like wearing long-term contact lenses. By simplifying diabetes management, the bionic pancreas has the potential to revolutionize the lives of countless individuals, allowing them to focus on their daily activities without the constant worry and interruptions associated with traditional diabetes care.
“We are thrilled to be part of the groundbreaking FORGETDIABETES initiative, which aligns perfectly with our mission to transform diabetes management through innovative and accessible technology,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “At Glucotrack, we are committed to redefining what life with diabetes can look like by providing simplified, discreet monitoring with our CBGM. Integration into automated insulin delivery systems is a key priority for us. We are honored to join FORGETDIABETES to develop a fully implantable closed loop system for people living with diabetes.”
Participants in the FORGETDIABETES initiative include the Department of Women & Child’s Health at University of Padova, Padova (Italy), the BioRobotics Institute at Sant’Anna School of Advanced Studies, Pisa (Italy), Pfützner Science & Health Institute GmbH, Mannheim (Germany), Centre Hospitalier Universitaire de Montpellier (France), Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (Germany) and WaveComm, SME, Siena (Italy).
The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
What is the FORGETDIABETES initiative that GCTK is participating in?
How will Glucotrack's CBGM technology contribute to the FORGETDIABETES project?
Which institutions are partnering with GCTK in the FORGETDIABETES initiative?
What is the funding source and amount for the FORGETDIABETES project involving GCTK?
How does the FORGETDIABETES initiative aim to improve type 1 diabetes management?
